RxDoctor Payments Data

Mary Wilson

Adult Health · San Angelo, TXNPI 1518191444

Payments from drug & device makers

$930in general payments, 2019–2025

Across 44 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$322
  • Merck$164
  • Novartis$132
  • Johnson & Johnson$59
  • Amgen$52
  • Boehringer Ingelheim$43
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$84291%
  • Education$879%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 65th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$24,281
Medicare patients
256
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$82,085
XareltoRivaroxaban53$39,783
EntrestoSacubitril/Valsartan16$15,556
Potassium Chloride82$1,360
Metoprolol Succinate108$1,359
Atorvastatin Calcium100$1,337
Ranolazine ErRanolazine22$1,171
Nifedipine ErNifedipine63$1,111
Losartan Potassium83$1,111
ClopidogrelClopidogrel Bisulfate74$1,027
Carvedilol87$894
Furosemide157$861
Spironolactone105$844
Rosuvastatin Calcium51$611
Isosorbide Mononitrate ErIsosorbide Mononitrate41$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$59$39,78353 claims
NovartisEntresto$132$15,55616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 933 adult health providers in Texas.

Other adult health in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →